Hans Hull Sells 15,936 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) insider Hans Hull sold 15,936 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the transaction, the insider now owns 211,558 shares in the company, valued at approximately $2,369,449.60. This represents a 7.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pliant Therapeutics Price Performance

Shares of PLRX opened at $11.14 on Friday. Pliant Therapeutics, Inc. has a fifty-two week low of $10.22 and a fifty-two week high of $18.92. The firm’s 50 day moving average price is $13.18 and its 200 day moving average price is $13.06. The company has a market cap of $677.87 million, a P/E ratio of -3.34 and a beta of 1.05. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09.

Pliant Therapeutics (NASDAQ:PLRX) last announced its earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.04. On average, research analysts forecast that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pliant Therapeutics

Large investors have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in shares of Pliant Therapeutics in the 4th quarter valued at approximately $33,000. Atria Investments Inc purchased a new stake in shares of Pliant Therapeutics in the 3rd quarter valued at approximately $112,000. Deerfield Management Company L.P. Series C purchased a new stake in shares of Pliant Therapeutics in the 2nd quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. increased its position in shares of Pliant Therapeutics by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Pliant Therapeutics in the 3rd quarter valued at approximately $145,000. 97.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.